47452-55-1Relevant academic research and scientific papers
NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS
-
Page/Page column 44-45, (2018/03/25)
The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R8, X, A and R11are as described herein, compositions including the compounds and methods of using the compounds as serine protease HtrAl inhibitors for the treatment or prophylaxis of HtrAl-mediated ocular diseases, such as wet or dry age-related macular degeneration, geographic atrophy, diabetic retinopathy, retinopathy of prematurity and polypoidal choroidal vasculopathy.
Pyrrolidine derivatives
-
, (2008/06/13)
The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.
Pyrrolidine derivatives
-
, (2008/06/13)
The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
Multiple binding modes for the receptor-bound conformations of cyclic AII agonists
Plucinska,Kataoka,Yodo,Cody,He,Humblet,Lu,Lunney,Major,Panek,Schelkun,Skeean,Marshall
, p. 1902 - 1913 (2007/10/02)
Angiotensin II, Asp-Arg-Val-Tyr-His-Pro-Phe, binds its receptor with a postulated turn centered at residue four. Analogs of angiotensin II which contain a disulfide bridge between the side chains of residues 3 and 5 retain significant activity consistent
